Cargando…

Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor

We report a gastrointestinal stromal tumor (GIST) patient with male gynecomastia and testicular hydrocele after treatment with imatinib mesylate. A 42 yr-old male patient presented for management of hepatic masses. Two years earlier, he had undergone a small bowel resection to remove an intraabdomin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hawk, Chang, Heung-Moon, Ryu, Min-Hee, Kim, Tae-Won, Sohn, Hee-Jung, Kim, So-Eun, Kang, Hye-Jin, Park, Sarah, Lee, Jung-Shin, Kang, Yoon-Koo
Formato: Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782215/
https://www.ncbi.nlm.nih.gov/pubmed/15953881
http://dx.doi.org/10.3346/jkms.2005.20.3.512
_version_ 1782174626971910144
author Kim, Hawk
Chang, Heung-Moon
Ryu, Min-Hee
Kim, Tae-Won
Sohn, Hee-Jung
Kim, So-Eun
Kang, Hye-Jin
Park, Sarah
Lee, Jung-Shin
Kang, Yoon-Koo
author_facet Kim, Hawk
Chang, Heung-Moon
Ryu, Min-Hee
Kim, Tae-Won
Sohn, Hee-Jung
Kim, So-Eun
Kang, Hye-Jin
Park, Sarah
Lee, Jung-Shin
Kang, Yoon-Koo
author_sort Kim, Hawk
collection PubMed
description We report a gastrointestinal stromal tumor (GIST) patient with male gynecomastia and testicular hydrocele after treatment with imatinib mesylate. A 42 yr-old male patient presented for management of hepatic masses. Two years earlier, he had undergone a small bowel resection to remove an intraabdominal mass later shown to be a GIST, followed by adjuvant radiation therapy. At presentation, CT scan revealed multiple hepatic masses, which were compatible with metastatic GIST, and he was prescribed imatinib 400 mg/day. During treatment, he experienced painful enlargement of the left breast and scrotal swelling. Three months after cessation of imatinib treatment, the tumors recurred, and, upon recommencing imatinib, he experienced painful enlargement of the right breast and scrotal swelling. He was diagnosed with male gynecomastia caused by decreased testosterone and non-communicative testicular hydrocele. He was given androgen support and a hydrocelectomy, which improved his gynecomastia. The mechanism by which imatinib induces gynecomastia and hydrocele is thought to be associated with an inhibition of c-KIT and platelet-derive growth factor. This is the first report, to our knowledge, describing concurrent male gynecomastia and testicular hydrocele after imatinib treatment of a patient with GIST.
format Text
id pubmed-2782215
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher The Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-27822152009-11-30 Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor Kim, Hawk Chang, Heung-Moon Ryu, Min-Hee Kim, Tae-Won Sohn, Hee-Jung Kim, So-Eun Kang, Hye-Jin Park, Sarah Lee, Jung-Shin Kang, Yoon-Koo J Korean Med Sci Case Report We report a gastrointestinal stromal tumor (GIST) patient with male gynecomastia and testicular hydrocele after treatment with imatinib mesylate. A 42 yr-old male patient presented for management of hepatic masses. Two years earlier, he had undergone a small bowel resection to remove an intraabdominal mass later shown to be a GIST, followed by adjuvant radiation therapy. At presentation, CT scan revealed multiple hepatic masses, which were compatible with metastatic GIST, and he was prescribed imatinib 400 mg/day. During treatment, he experienced painful enlargement of the left breast and scrotal swelling. Three months after cessation of imatinib treatment, the tumors recurred, and, upon recommencing imatinib, he experienced painful enlargement of the right breast and scrotal swelling. He was diagnosed with male gynecomastia caused by decreased testosterone and non-communicative testicular hydrocele. He was given androgen support and a hydrocelectomy, which improved his gynecomastia. The mechanism by which imatinib induces gynecomastia and hydrocele is thought to be associated with an inhibition of c-KIT and platelet-derive growth factor. This is the first report, to our knowledge, describing concurrent male gynecomastia and testicular hydrocele after imatinib treatment of a patient with GIST. The Korean Academy of Medical Sciences 2005-06 2005-06-30 /pmc/articles/PMC2782215/ /pubmed/15953881 http://dx.doi.org/10.3346/jkms.2005.20.3.512 Text en Copyright © 2005 The Korean Academy of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kim, Hawk
Chang, Heung-Moon
Ryu, Min-Hee
Kim, Tae-Won
Sohn, Hee-Jung
Kim, So-Eun
Kang, Hye-Jin
Park, Sarah
Lee, Jung-Shin
Kang, Yoon-Koo
Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor
title Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor
title_full Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor
title_fullStr Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor
title_full_unstemmed Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor
title_short Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor
title_sort concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782215/
https://www.ncbi.nlm.nih.gov/pubmed/15953881
http://dx.doi.org/10.3346/jkms.2005.20.3.512
work_keys_str_mv AT kimhawk concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor
AT changheungmoon concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor
AT ryuminhee concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor
AT kimtaewon concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor
AT sohnheejung concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor
AT kimsoeun concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor
AT kanghyejin concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor
AT parksarah concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor
AT leejungshin concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor
AT kangyoonkoo concurrentmalegynecomastiaandtesticularhydroceleafterimatinibmesylatetreatmentofagastrointestinalstromaltumor